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Abstract
The oral cavity is home to vast populations of commensal microbial organisms which con-
stitute the ‘healthy oral microbiome.’ Periodontitis is a destructive, infectious, inflamma-
tory condition affecting the gums. Initially, a biofilm structure develops, causing localized 
inflammation. This biofilm is then colonized by certain anaerobic bacteria, including the 
‘red complex’ organisms. There is an increasing interest in the communication between 
these organisms and host immune surveillance, a dialog which may plays an important 
role in the development of autoimmune diseases. Studies have shown an association 
between periodontitis and other inflammatory conditions including rheumatoid arthritis, 
psoriatic arthritis, ankylosing spondylitis and systemic lupus. The advent of accessible 
16S ribosomal sequencing has led to exciting developments in the characterization of the 
human microbiome and the ability to study this interaction in more detail. The transmu-
cosal communication between periodontitis and host immunity may provide avenues of 
discovery regarding the etiology and progression of rheumatic diseases.
Keywords: Porphyromonas gingivalis, gums, biofilm, periodontal membrane, microbiome, 
rheumatology, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic 
lupus erythematosus, osteoarthritis
1. Introduction
It is known that the human body is covered with microbes. Until recently, many of these 
have been thought of as indolent, ‘commensal’ organisms, living in harmony with the host 
and thought of little relevance. If we consider that a single human being consists of approxi-
mately 1 trillion human cells but 10 trillion bacterial cells and, at a genetic level, 20,000 human 
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genes but between 2 and 20 million bacterial genes, the indolence of these bacteria has to be 
 questioned. There is therefore increasing interest in the roles played by these microorganisms 
on host immunology and physiology.
The oral mucosa is home to vast populations of these ‘commensal’ microbial organisms. It is 
therefore an arena which is ripe for communication between foreign organisms and host immune 
surveillance, a dialog which may play an important role in the development of  autoimmune 
diseases.
The thrust of this chapter is to provide an update on the current literature regarding the role of 
microbiota in rheumatological conditions including rheumatoid arthritis, psoriatic  arthritis, 
ankylosing spondylitis, osteoarthritis and systemic lupus.
2. The human microbiome
The term ‘microbiome’ refers to the sum of bacterial communities that colonize a particular 
area [1]. In humans, this includes almost any surface, for example, the skin, gut, airways, geni-
tourinary tract and oral cavity. It is estimated that the human body is comprised of 1  trillion 
human cells [1], with genetic material accounting for approximately 20,000 human genes [2]. 
The bacteria which colonize the human body are estimated to contribute a further 20 trillion 
cells and between 2 and 20 million bacterial genes [1]. This does not include estimates of 
fungi and viruses which inhabit the human corpus. This had led to conjecture that a human 
is not simply ‘an organism’ but rather ‘a superorganism’ comprised of multiple separate 
 organisms. Whether this is the case or not, it is certainly conceivable that the microorganisms 
that colonize the various niche environments of the human body contribute to physiology, 
 biochemistry and immunity.
Study of the bacterial microbiome was previously limited by culture-dependent techniques 
which are limited in their ability to identify beyond the most prevalent organisms or that are 
amenable to culture in the media available. However, there have been exciting developments 
in the characterization of the human microbiome with the relatively recent advent of  accessible 
16S ribosomal sequencing.
Prokaryotic cells contain 70S ribosomes which consist of larger 50S and smaller 30S subunits 
[3]. The latter is comprised of 22 ribonucleoproteins and 16S ribosomal RNA. Due to the slow 
rate of evolution and highly conserved primer binding sites, 16S ribosomal RNA has been 
developed as a tool for phylogenetic studies [4]. With developments in the processes of RNA 
extraction, amplification with 16S rRNA primer and high-throughput sequencing, this has 
become an increasingly available method of bacterial identification, providing proportionally 
quantitative data on all bacteria in a sample. Identification libraries are growing and initia-
tives including the human microbiome project (HMP) [5] in the USA and metagenomics of 
the human intestinal tract (MetaHIT) [2] in Europe aim to catalogue the microbiomic constitu-
ents of the human body in health and disease. Of course, in order to identify changes in the 
microbiome related to disease, the spectrum of normality must first be established.
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The human microbiome represents a previously unexplored arena which may provide 
 discoveries relating the etiology, progression and management of human disease. However, 
it must be recognized that the horizons of human-microorganism interaction are vast and 
include bacterial proteomics, metabolomics, not to mention the human virome. Much 
endeavor is required to delineate the role played by these organisms in human diseases, 
including rheumatoid arthritis and periodontitis.
3. Periodontitis and the oral microbiome
3.1. Periodontitis
The periodontium is made up of the gingiva and the underlying attachment tissues. Gingivitis 
is a reversible form of gingival inflammation characterized by redness, swelling and  bleeding. 
Periodontitis occurs once the inflammation extends to the deeper tissues including the peri-
odontal ligament and alveolar bone. The loss of periodontal attachment and bone produces 
deepening of the gingival sulcus (periodontal pocket) and progressive loosening of teeth 
eventually leading to their loss [6].
The prevalence of periodontitis varies internationally; however, approximately 10–15% of the 
global adult population are affected by the condition [7]. The etiology is multifactorial and is 
composed of genetic predisposition, bacterial dysbiosis associated with a specific local and 
systemic host response and environmental factors [8] Although there is a genetic element to 
periodontitis, it is usually polygenic and so difficult to predict. Known risk factors include 
smoking, age, diabetes mellitus, educational level, gender and immunological  diseases 
(e.g., HIV) [7, 9].
Plaque-induced periodontitis is the most common presentation. Initially, a biofilm structure 
develops which causes localized inflammation in the form of gingivitis. This biofilm is then 
colonized by anaerobic bacteria which causes further inflammation and neutrophilic activa-
tion. Matrix metalloproteinases are spilled, leading to tissue destruction, exacerbating the 
attachment loss and deepening the periodontal pocket. These results in further anaerobic 
colonization, soft tissue destruction, alveolar bone loss and ultimately tooth loss [8].
Management of periodontitis is aimed at excellent oral hygiene with twice-daily brushing of 
teeth and use of interdental brush and flossing. Plaque removal with scaling and debridement 
can be used to prevent excessive buildup of plaque. Low-dose doxycycline can inhibit matrix 
metalloproteinases such as collagenase and therefore reduce tissue damage. In severe cases 
and nonresolving gingival inflammation, there are surgical options which could allow for 
some regeneration of the lost soft and hard tissues [8].
3.2. The oral microbiome
The oral microbiome is composed of the microorganisms found in the oral cavity, or as defined 
by Joshua Lederberg ‘the ecological community of commensal, symbiotic, and pathogenic 
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microorganisms that literally share our body space ‘[10]. Although about 280 species have 
been cultured, it is estimated that they make up less than half of the bacterial species present 
in the oral cavity and the true number is likely to be between 500 and 700 [11, 12].
The advent of next generation sequencing has allowed the development of the human micro-
biome project. Findings suggest that although each individual body site is colonized by a 
characteristic microbiome, it is the individual who is colonized which is the primary factor 
affecting the bacterial makeup [11]. In the mouth, there are three distinct bacterial communi-
ties: the buccal mucosa, gingivae and hard palate forming one; the saliva, tongue, tonsils and 
throat forming another; and lastly the supra- and subgingival plaque [13].
Ninety-six percent of the bacterial community of the mouth is the phyla Firmicutes, Bacteroidetes, 
Proteobacteria, Actinobacteria, Spirochaetes and Fusobacteria [11, 14]. The composition of bacteria 
in ‘healthy’ and ‘diseased’ sites in the mouth is shown in Table 1.
Of these bacteria, there is the most evidence that Porphyromonas gingivalis has a key role to 
play in the pathogenesis of periodontitis and that with ‘accessory pathogens’ it alters the host 
immune response [8]. For example, P. gingivalis has specifically been implicated in blocking 
complement activation and inhibiting complement function [9].
‘Healthy’ sites; more gram-
positive organisms
Dental caries Gingivitis; gram-positive 
aerobes, facultative 
anaerobes, gram negatives
Periodontitis; gram-
negative and anaerobic 
organisms
Actinomyces Streptococcus mutans Actinomyces Porphyromonas gingivalis*
Streptocci Streptococcus sobrinus Streptococci Porphyromonas 
endodontalis
Veillonella Actinomyces Treponema Tannerella forsythia*
Granulicatella Lactobacillus acidophilus Synergistetes Treponema denticola*
Corynebacterium Bifidobacterium Aggregatibacter 
actinomycetemcomitans*
Fusobacterium Propionibacterium Anaeroglobus geminatus
Gamella Veillonella Eubacterium saphenum
Rothia Filifactor alocis
Porphyromonas Prevotella denticola
Prevotella Prevotella nigrescens
Staphylococcus Fusobacterium nucleatum
Lactobacterium
Haemophilis
Peptostreptococcus
*Red-complex organisms implicated in periodontitis [11–14].
Table 1. Selection of bacteria found in oral microbiome in health and disease.
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3.3. Measures of periodontitis
In order to carry out high-quality studies investigating the association of periodontitis with 
other conditions, it is imperative to have valid and reliable measures of periodontitis.
There are a number of measures, shown in Table 2, which have been developed, looking at 
both gingivitis severity and periodontal disease [15, 16].
These measures have significant limitations. Multiple confounders such as age, smoking 
and immunosuppressant therapy can make them very difficult to interpret [7, 17]. Some 
 measures under- or overestimate periodontal disease as they are affected by gum recession 
alone. However, the most significant limitation is that there is no single gold standard defi-
nition of a threshold for a diagnosis of ‘periodontitis’. Most studies use varying thresholds 
which has a  significant impact on prevalence rates and means studies need to be compared 
with caution [18].
Measure Definition Method Characteristic
Gingivitis Bleeding on probing 
(BOP)
Bleeding of gingiva  
on gentle probing
Bleeding within 10 
seconds, following 
gentle probing of 
gingival crevice
Assessment of gingivitis
Bleeding index BOP, calculated as  
an index
Number of sites BOP, 
divided by the total 
number of available 
sites multiplied by 100
Assessment of gingivitis
Loe and Sillness 
Gingival index
Degree of gingival 
inflammation, 
characterized 
by erythema, 
hypertrophy and 
bleeding
Degree of inflammation 
given score out of four. 
The scores of four 
areas of the tooth are 
averaged
Assessment of gingivitis
Periodontitis Missing teeth Number of missing 
teeth
Count missing teeth Crude, may be due 
to reasons other than 
periodontal disease
Alveolar bone loss Loss of the bone 
which supports the 
teeth
Periapical radiograph Associated with tooth 
loss secondary to 
periodontitis
Probing depth (PD) Depth of the 
periodontal pocket
Measure the distance 
from the gingival 
margin to the base of 
the pocket
Measure of current 
periodontitis
Clinical attachment 
level (CAL)
Measurement of the 
position of the soft 
tissue in relation to 
the cementoenamel 
junction (CEJ)
Calculated using the 
probing depth and the 
level of the gingival 
margin
Measure of cumulative 
periodontal disease
Table 2. Gingivitis and periodontal disease clinical measures [15, 16].
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4. Periodontitis and systemic inflammation
The interest in the systemic inflammatory profile of patients affected by periodontitis has risen 
in the last 30 years to investigate the plausibility of the hypothesis that periodontal infection 
might have an impact on the systemic health. Particularly, the effect of periodontitis on the 
cardiovascular system but more recently a large spectrum of conditions such as neurodegener-
ative diseases, diabetes mellitus and rheumatoid arthritis, has been investigated. All these dis-
eases are characterized by an increased systemic inflammatory profile, and periodontitis could 
contribute to their onset and progression by elevating pro-inflammatory markers. Consistent 
evidence from observational studies has suggested that severe periodontitis is associated 
with increased serum levels of C-reactive protein (CRP), moderate leukocytosis, as well as 
increased serum levels of interleukin-1 (IL-1) and IL-6 [19–23]. Furthermore, elevated serum 
levels of CRP have been associated with presence of keystone periodontal pathogens [24].
A recent systematic review confirmed a weighted mean difference of 1.56 mg/l (p < 0.00001) 
of CRP levels between cases with periodontitis and controls [25]. Further, the review reported 
on data from six intervention studies, concluding that periodontal treatment produced a 0.50 
mg/l (95% CI 0.08–0.93) (p < 0.02) reduction of CRP serum levels. A recent meta-analysis on 
the effects of periodontal therapy and systemic inflammation reported a 0.23-mg/l reduction 
in CRP levels after treatment (−0.231; p = 0.000) [26]. Interestingly, a further analysis confirmed 
that the anti-inflammatory effect of periodontal treatment was more evident in clinical trials 
involving patients with periodontitis and other comorbidities like diabetes [27]. Individuals 
with periodontitis also show increased serum concentration of IL-6 and TNF-α compared to 
controls. Intervention trials reported inconclusive results on the effect of periodontal treat-
ment on serum levels of these markers [28].
Different plausible mechanisms by which periodontitis could cause an increase in systemic 
inflammatory levels have been suggested. Firstly, multiple studies have reported the produc-
tion of inflammatory cytokines in the periodontal pocket [29] and it has been postulated that 
these mediators could reach the bloodstream leaking from the inflamed periodontal lesions. 
Some of these mediators (i.e., IL-6) could have an effect on distant tissues and organs such as 
the liver, triggering an acute-phase response. However, for the time being, there is a limited 
evidence supporting this mechanism [30].
Secondly, bacteria colonizing the periodontal pockets and/or their by-products have been 
detected in the peripheral circulation [31]. A disruption of the subgingival epithelium could 
lead to short-lived bacteremia. This could trigger an immune response as well as allow bacteria 
to directly impact on the vasculature or distant organs (like the liver or kidney). In support of 
this hypothesis, periodontal bacteria DNA [32] and viable pathogens [33] have been detected in 
human atherosclerotic plaques. Thirdly, several antibodies induced by periodontal pathogens 
might trigger a molecular mimicry with cross-reactive antibodies recognizing host antigens.
Lastly, periodontitis and other comorbidities such as cardiovascular diseases and diabetes, 
share many common risk factors, including obesity and smoking [34, 35] which both have an 
effect on the systemic inflammatory profile [36]. This might account for a spurious association 
between periodontitis and systemic inflammation. However, the majority of the observational 
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and experimental evidence available seems to support the concept that periodontitis could 
independently contribute to systemic levels of different inflammatory mediators and that peri-
odontal treatment could result in their reduction. The systemic low-grade inflammation generated 
by periodontal infection might represent the link between periodontitis and systemic condi-
tions [37, 38].
5. Periodontitis and rheumatoid arthritis
5.1. Rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and 
destruction with extra-articular features including rheumatoid nodules, pulmonary disease, 
vasculitis and neuro-inflammation [39]. It can lead to chronic disability, early mortality, sys-
temic complications and high socioeconomic burden on society as a whole [40]. The preva-
lence of RA is 0.5–1.0% [13] with apparent variation according to latitude and urban/rural 
habitation [41, 42].
It is currently classified according to the 2010 American College of Rheumatology/European 
League against rheumatism criteria by joint involvement, positive serology for rheumatoid 
factor or anti-citrullinated protein antibodies (ACPA), raised acute-phase reactants and the 
duration of symptoms [43]. Treatment regimens traditionally include corticosteroid to induce 
remission used in combination with maintenance of disease-modifying antirheumatic drugs, 
though have been much improved by the intervention of biologic agents.
5.2. Pathogenesis of rheumatoid arthritis
The exact etiology of RA is unknown; however, it is thought to be secondary to an interaction 
between genetic attributes and environmental exposures.
Indeed, genetic studies in twins have estimated approximately 60% heritability of rheumatoid 
arthritis [44]. Genetic polymorphisms including HLA-DRB1 [45] are implicated. However, 
other susceptibility alleles including genes involved in the differentiation of T cells, selection 
of antigens and peptide affinity have been identified by genome-wide association studies.
In terms of environmental insults, smoking has long been associated with RA [46] as have social 
factors including lower socioeconomic class and education but other areas of interest include 
silica, exogenous infections, periodontitis and the microbiota of mouth, gut and lung [47].
Autoantibodies to the Fc portion of immunoglobulin are known as rheumatoid factor and 
antibodies that are known to form against citrullinated proteins are called anti-citrullinated 
protein antibody (ACPA) or anti-cyclic citrullinated peptide (anti-CCP) antibodies. If either of 
these are present, they confer ‘seropositivity,’ which is seen in 70–80% of patients [48]. In addi-
tion to forming an element of the diagnostic criteria [43], seropositivity is also associated with 
more aggressive disease and with the earlier development of erosions. Rheumatoid factor is 
limited in diagnostic application by low specificity; however, ACPA is 95–98% specific [49].
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ACPA has been shown to be present in RA patient sera up to a decade prior to the develop-
ment of the disease [50] although the amount of ACPA and inflammatory cytokine levels 
rise sharply a few months before the synovitis presents [51]. It is therefore hypothesized that 
as well as citrullination of endogenous proteins, a second inflammatory ‘hit’ is required to 
stimulate the development of RA. Citrullinated proteins are also associated with other envi-
ronmental factors such as smoking and pathological conditions including periodontitis.
Peptidyl arginine deiminase (PAD) causes the posttranslational modification of arginine to 
citrulline. It is hypothesized that this citrullination leads to amino acid chains being recognized 
as autoantigens, which leads to the development of autoantibodies and the subsequent auto-
immune damage that is the signature for rheumatoid arthritis. PAD is produced by human 
cells, for example, in the lung; however, it is also produced by the microbe P. gingivalis [52].
Mucosal surfaces provide a rich opportunity for cross-talk between the immune system and 
the microorganisms which inhabit them. It is supposed that these microbes are not simply left 
unattended and indolent, but are held in a constant state of tension by physiological barriers 
(mucus and immunoglobulin A), epithelial tight junctions, innate immune surveillance (by 
macrophages and dendritic cells) and adaptive immune response.
The mucosal-joint axis hypothesis is supported by the fact that 20% of chronic inflamma-
tory bowel disease patients develop an enteropathic arthropathy and that reactive arthritis 
can develop in response to chlamydial and dysenteric organism. A possible mechanism is 
therefore that disruption in pathogenic-commensal bacterial balance at the mucosal surface 
leads to innate activation and pro-inflammatory cytokine release, leading to a lasting adaptive 
immune response. If we then consider that some bacterial epitopes are shared with cartilage 
[53], it is possible that the adaptive immunity, in response to transmucosal exposure to a 
microorganism, could lead to sustained autoimmunity.
5.3. P. gingivalis and rheumatoid arthritis
PAD production by P. gingivalis, an anaerobic prokaryote, has been demonstrated in vitro. 
Due to this organism’s role in the development of periodontal disease and the association of 
rheumatoid arthritis with periodontitis, it has been hypothesized that P. gingivalis provides a 
causal link between periodontal disease, citrullination and RA [54].
The temporal nature of this association is a point of conjecture, though it has been shown that 
non-RA (as defined by the American College of Rheumatology (ACR) criteria) patients with risk 
factors for the development of RA such as first-degree relatives and ACPA positivity had a higher 
concentration of anti-P. gingivalis antibodies [55]. This finding suggests that P. gingivalis (one of the 
‘red complex’ organisms) appears prior to the development of rheumatoid arthritis in an ‘at risk’ 
population. Indeed, an etiological role of P. gingivalis is implicated by the recent finding that anti-
P. gingivalis antibodies are significantly higher in RA cases compared to controls and, similar to 
ACPA, are present in sera years before the onset of symptoms of inflammatory arthropathy [56].
In addition to an etiological role, there is longitudinal evidence to suggest that P. gingivalis 
PAD may attenuate response to biologic Disease-modifying anti rheumatic drugs [57].
Periodontitis - A Useful Reference120
Together, these elements suggest a role for this organism in various aspects of rheumatoid 
disease and pronounce P. gingivalis as a viable avenue for further research.
5.4. Periodontitis in rheumatoid arthritis
Epidemiological studies have shown a strong association between periodontitis and RA [58, 59], 
though these have been hampered by their cross-sectional nature, variability in definition of 
periodontitis and dental endpoints, the extent of oral examination and the limited RA infor-
mation collected. However, despite the above, there remains a significant amount of robust 
evidence to support the association between periodontitis and RA including a recent meta-
analysis of 17 studies and over 150,000 participants, found a significant association between 
RA and periodontitis with a relative risk of 1.13 (95% CI 1.04–1.23, p = 0.006) compared to 
healthy controls [60].
Shared risk factors, including cigarette smoke, provide possible confounders; however, an 
increased risk of periodontitis has been demonstrated in a nonsmoking RA group [61], and a 
comparison of periodontitis in osteoarthritis versus RA demonstrated that RA patients were 
twice as likely to have moderate to severe periodontitis independent of smoking, age or sex 
[62]. In addition, there is evidence to suggest that periodontitis responds to RA treatment [63].
5.5. Oral microbiome in rheumatoid arthritis
The association of periodontitis and P. gingivalis with rheumatoid arthritis has led to a great 
deal of interest in the oral microbiome in rheumatoid disease. Indeed, oral bacterial DNA 
and antibodies to P. gingivalis, T. forsythia and P. intermedia have been demonstrated in syno-
vial fluid and the site of inflammation in rheumatoid arthritis [64]. It is also interesting that 
the medications with an antibacterial action against these species (including levofloxacin and 
clarithromycin) seem to have a beneficial effect in RA [65].
Animal studies have demonstrated a possible role periodontal bacteria in inflammatory 
arthritis. In a murine model of collagen-induced arthritis, oral infection with bacteria 
associated with periodontitis in humans developed exacerbated signs of inflammatory 
arthropathy, raised levels of matrix metalloproteinase 3 and histological evidence of active 
arthritis [66].
A study by Scher and colleagues used 16S ribosomal RNA sequencing to investigate oral 
microbiota from the subgingival plaque in patients with new-onset, Disease-modifying 
anti rheumatic drug naïve rheumatoid arthritis [67]. They found significantly higher lev-
els of Prevotella and Leptotrichia species in the new-onset RA group compared to controls, 
which was robust to adjustment for periodontal disease status. In addition, Streptococcus and 
Corynebacterium genera were reduced in the new-onset RA group compared to healthy con-
trols. They also investigated a chronic RA (Disease-modifying anti rheumatic drug treated) 
group and found higher levels of red complex bacteria in the new-onset RA group compared 
to the established disease group. These findings illustrate the changes in subgingival micro-
biota over time, and further work is required to delineate any independent roles of these 
changes in the microbial landscape.
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Investigations of the oral microbiome are potentially hampered by the site of sampling as the 
oral microbiome varies depending on the region sampled. The gingival sulcus, tooth surface, 
hard and soft palate, saliva and tonsils are home to significantly different compositions of 
bacterial populations at a baseline. With the addition of the increased expertise required to 
acquire samples, there are far fewer studies investigating the oral microbiome than the gut 
microbiome in RA.
5.6. Gut microbiome in rheumatoid arthritis
The gut microbiome is the most densely populated microbial environment in the human body 
and is the most extensively studied. The benefit of extensive investigation is that the spectrum 
of the bacterial constituents of a ‘normal’ gut microbiome is more clearly defined [68] than in 
the oral cavity.
Disruption of the gut microbiome has been demonstrated in patients with rheumatoid arthritis 
compared to controls [69], and preceding work in animal models has highlighted possible 
etiological mechanisms of action.
For example, manipulating the gut microbiome by instilling segmented filamentous bacteria 
into the small intestine of mice induces CD4 T cells which produce the pro-inflammatory 
cytokine IL-17 in the intestinal lamina propria [70]. The experimental creation of small bowel 
bacterial overgrowth leads to reactivation of resolved arthritis in a rat model [71]. The resultant 
proposed hypothesis is that bacterial overgrowth leads to systemic, transmucosal absorp-
tion of Lipopolysaccharide which deposits in the liver and joints, leading to an inflammatory 
response.
Subtraction of microbiota as well as addition can lead to a pro-inflammatory phenotype, as 
in an adjuvant-induced arthritis, rat model, gnotobiotic (germ-free) rats demonstrated signifi-
cantly greater joint inflammation than those with normal gut microbiota [72].
Analysis of the fecal microbiome of patients with rheumatoid arthritis found that haemophi-
lus species were significantly reduced and lactobacillus species were significantly increased 
[69]. This study also showed that the intestinal dysbiosis was attenuated by Disease-modifying 
anti rheumatic drugs. Prevotella copri is raised in new-onset RA [73] and correlated with shared 
epitope genes, drawing attention to the organism as a potential environmental trigger for the 
development of RA.
The rapidly engorging literature regarding the gut microbiome and rheumatoid arthritis acts 
as encouragement to investigate other mucosal surfaces, and, with the marked associations 
with periodontitis and oral bacteria, the oral microbiome is a viable candidate for investigation.
5.7. Potential interventions
In addition studies to delineate the role of the microbiome in the etiology and progression of 
RA, it is worth considering the possible therapeutic interventions which could be developed.
Antibiotic administration is an apparent start, and doxycycline (which was historically used 
to treat RA) when used in conjunction with methotrexate has been shown to outperform 
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methotrexate alone [74]. In patients with mild-to-moderate RA, minocycline was shown 
to significantly improve joint swelling, tenderness and erythrocyte sedimentation rate in a 
placebo-controlled trial [75]. However, the use of broad spectrum antibiotics introduces the 
risk of depleting all elements of the microbiome and opening the door to hostile organism 
invasion.
Other postulated interventions include probiotics, fecal microbiota transplant [64], harness-
ing bacterial secretions and single-target approaches to modify bacterial composition and by-
products. Although they are exciting opportunities for research, these approaches are still in 
relative infancy.
5.8. Conclusion
There are strong data to support the association between rheumatoid arthritis, periodontitis 
and P. gingivalis. The role of mucosal immunity in the development of autoimmunity has been 
demonstrated extensively in the gut, and similar pathogenic processes could occur in the oral 
mucosa, though further investigation is required to clarify the role played by the oral microbiome 
in RA.
6. Periodontitis and ankylosing spondylitis
6.1. Ankylosing spondylitis
Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the spine 
and sacroiliac joints. It is characterized by inflammatory back pain caused by enthesitis, bone 
erosion and new bone formation. Clinical features also include peripheral arthritis, anterior 
uveitis and rarely lung fibrosis, heart block and aortic regurgitation [76].
The overall prevalence of AS is between 0.1 and 1.4% with most cases coming from Europe 
[77]. Onset occurs young with 80% of patients presenting before the age of 30 and less than 
5% present after the age of 45. Men are 2–3 times more commonly affected than women [77].
The diagnosis of AS is based on clinical features and presence of sacroiliitis on X-ray or MRI 
[78]. Treatment options are still limited, and emphasis is placed on physiotherapy and nonste-
roidal anti-inflammatory medications, with anti-TNF therapy reserved for those who experience 
a persistently high level of disease activity. However, these have many potential side effects 
[78] and further understanding of the etiology of AS is needed in order to develop other treat-
ment options.
6.2. Pathogenesis of ankylosing spondylitis
More than 90% of the risk of developing ankylosing spondylitis is determined genetically 
[79]. An important contribution of this is from human leucocyte antigen B27 (HLA-B27), a 
class 1 surface antigen encoded by MHC which has a role in presenting antigens to CD8 T 
cells. HLA B-27 is present in 90–95% of patients with AS, and the risk of developing AS in 
Periodontal Disease and Autoimmunity: What We Have Learned from Microbiome Studies...
http://dx.doi.org/10.5772/intechopen.69012
123
HLA-B27-positive individuals is 2–5%. This is increased to 15–20% in HLA-B27-positive first-
degree relative of AS patients [77].
The remainder of the risk comes from environmental factors. There is already substantial 
evidence to support a role of bacteria in the pathogenesis of AS. Reactive arthritis, another 
subtype of spondyloarthropathy, is triggered by genitourinary infections or enteritis caused 
by gram-negative enterobacteria. It is believed that the persistence of microbial antigens in 
the synovium of these patients contributes to the propagation of inflammation [77]. The pos-
sible role of these bacteria in the pathogenesis of AS is highlighted by the fact that 10–20% of 
HLA B27-positive patients with reactive arthritis develop the full clinical picture of ankylos-
ing spondylitis [80]. Furthermore, 54% of HLA B27-positive patients with Crohn’s disease 
develop ankylosing spondylitis, possibly due to the inflammatory processes in the gut allow-
ing interaction of the gut bacteria and immune system [81]. TNF-alpha and T cell response is 
thought to be an important driver of inflammation in AS.
6.3. Periodontitis and ankylosing spondylitis
The similarities in the pathogenesis of ankylosing spondylitis and periodontitis have led to 
the hypothesis that periodontitis may allow oral bacteria access to the immune system and 
perpetuate inflammatory processes in those patients with genetic susceptibility. HLA A9 and 
B15, both associated with susceptibility to AS, may also be a susceptibility factor in aggressive 
periodontitis [82]. In particular, T lymphocyte-driven inflammation certainly plays a role in 
periodontitis [83] as well as in AS [84]. Interleukin (IL)-2, IL-6 and TNF-α are all raised in AS 
[85] as well as being implicated in periodontitis [86]. In fact, anti-TNF therapy in AS patients 
leads to a significant improvement in periodontal disease markers [87].
Ratz et al. performed a meta-analysis in 2015 of 6 studies comparing periodontitis measures in 
cases of AS and controls, and ranging in size between 90 and 40,926 participants [18]. All stud-
ies showed a positive correlation between AS and periodontitis severity, but only two showed 
statistical significance. On meta-analysis, the risk of developing AS in those with periodontitis 
was almost double with an overall odds ratio of 1.85 (CI 1.72–1.98). Despite no significant dif-
ference in probing depth and Clinical attachment level (CAL), there was a significant associa-
tion in Bleeding on probing (BOP) with those with AS (p = 0.0005) [18].
Other studies since have looked further at the association between spondyloarthropathies, of 
which AS is a subtype, and periodontitis. In a group of 30 patients with spondyloarthropathy 
of which 8 had a diagnosis of AS, those patients with more than 5 years of evolution of dis-
ease had significantly worse periodontal disease [88]. In contrast, another group found that 
in 79 spondyloarthropathy patients, of which 19 had AS, levels of insertion loss were lower 
compared to the control group [89]. The association with P. gingivalis is still not certain, with 
contrasting findings that antibody titers were higher and lower in AS compared to controls 
[89, 90]
Recently, the oral microbiome has been studied in patients with axial spondyloarthritis. 
Patients were matched for age, gender and ethnicity to healthy controls. Interestingly, 
although patients had significantly greater prevalence of periodontitis (PPD ≥ 4 mm at ≥4 
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sites), a higher plaque index and higher mean bleeding on probing [91], there was no dif-
ference in either community structure or in diversity of organisms in the plaque bacterial 
communities analyzed. However, it is important to note that the small sample size in this 
study made it unlikely that any small effect size would be measured and so further larger 
studies are warranted to investigate this.
6.4. Conclusion
Overall, evidence does suggest an association between periodontitis and AS. When small 
studies were combined in meta-analysis, a significant odds ratio was calculated. Shared 
pathogenic mechanisms may explain some of this association, but the details of the underly-
ing processes remain largely unknown.
7. Periodontitis and psoriatic arthritis
7.1. Psoriatic arthritis
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with the presence of psoria-
sis, usually prior to joint involvement. Ninety-five percent are a peripheral arthritis, usually 
involving more than five joints in an asymmetrical pattern. The spine and sacroiliac joints are 
also affected in about 5% of patients [92].
Psoriatic arthritis is uncommon in the general population affecting <1%. However, it occurs in 
up to 30% of patients with psoriasis. It occurs equally in men and women and most commonly 
in those between 30 and 50 years of age [93].
Diagnosis is made clinically by the presence of inflammatory joint pain, personal or family 
history of psoriasis and typical X-ray findings. The treatment can be subdivided firstly into 
the treatment of psoriasis and secondly into the treatment of arthritis with Non-steroidal anti-
inflammatory drugs, disease-modifying anti rheumatic drugs and biologics [94]. Again, the 
treatment options for PsA are limited and further understanding of disease etiology may lead 
to alternative treatments.
7.2. Pathogenesis of psoriatic arthritis
Similarly to the other seronegative spondyloarthropathies, psoriatic arthritis is thought 
to be caused by an environmental trigger in a genetically primed individual. Indeed, 
about 15% of first-degree relatives of a patient with psoriatic arthritis will also be affected 
and studies have elucidated genetic variants [93]. The most important of these are on 
the human leucocyte antigen 1 (HLA-1) which is involved in presenting antigens to CD8 
T cells. Variants such as HLA-Cw6, HLA-B27 and HLA-B39 are associated with specific 
phenotypes of PsA. These variants highlight that psoriatic arthritis is not just a subset of 
psoriasis and provide important clues as to the pathogenesis of PsA in which the CD8 T 
cell plays a key role [93].
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It is hypothesized that the molecules encoded by these HLA variants may recognize self-anti-
gens in the synovium and enthesis. However, the true pathogenesis is likely to be more complex 
as T cell expanded clones in the synovial tissue of patients with psoriatic arthritis lack common 
motifs to explain a single trigger. Fitzgerald and Winchester propose that in fact CD8 T cells 
are stimulated through NK receptors which respond to molecules produced in inflammation 
and stress [93]. In support of this, both physical trauma and immunization with rubella vaccine 
have been shown to proceed development of psoriatic arthritis. Stimulation of the inflammatory 
response leads to infiltration of T cells and cytokines including TNF-alpha, Il-1, IL-6, IL-12, IL-15, 
IL-17, IL-18 and IF-γ in the synovium and ultimately to the clinical finding of synovitis [93]
7.3. Periodontitis and psoriatic arthritis
The characteristic lymphocytic infiltration of the joint with activated T cells and thus with 
the secretion of the pro-inflammatory cytokines IL-1 and TNF-α potentiates abnormal bone 
remodeling and the activation of matrix metalloproteinases in PsA. Interestingly, chronic 
periodontitis has a similar cytokine profile which has led to research investigating the rela-
tionship between them.
In 2013, Ustun et al. compared the periodontal status of 51 patients with PsA to that of healthy 
controls. Clinical attachment level, the gold standard measure of periodontitis severity and 
past disease activity, was significantly greater in those with PsA (p = 0.037). Although not sta-
tistically significant, probing depth was greater in those with PsA [95]. In another study, prob-
ing depth was statistically greater in patients with PsA [96]. A much larger Danish nationwide 
cohort study including 6428 patients with PsA found that incidence rates of periodontitis 
were significantly greater in patients with PsA compared to reference population. Of note, 
periodontitis rates were also greater in patients with PsA compared to psoriasis alone [97].
One cause for this may be the trapping of oral bacterial DNAs in synovial fluid. Mean number 
of oral bacterial species is significantly higher in both sera and synovial fluid of PsA patients, 
and periodontitis-associated species P. gingivalis and Prevotella nigrescens have been exclu-
sively detected in PsA sera and synovial fluid [98].
A systematic review in 2016 presented 10 studies which all showed an association between pso-
riasis and periodontitis [99]. Eight of these, with between 33 and 115,365 cases, found measures 
of periodontitis including probing depth and CAL were increased in those with psoriasis com-
pared to controls [95, 100–106]. A large population cohort study concluded that self-reported 
alveolar bone loss and loss of teeth increased risk of subsequent psoriasis [104]. Furthermore, 
these studies concluded that the presence of psoriasis was associated with greater severity of 
periodontitis.
7.4. Conclusion
Although there are still a limited number of studies, those which have been carried out pro-
vide strong evidence for an association between PsA and periodontitis. Importantly, they also 
highlight the distinct association of PsA, rather than psoriasis, with periodontitis.
Periodontitis - A Useful Reference126
8. Periodontitis and systemic lupus erythematosus
8.1. Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a multi-systemic, chronic inflammatory condition which 
primarily affects connective tissues and is associated with specific serological signatures. Clinical 
features are extremely varied but common features include facial rash, oral ulcers, photosensitiv-
ity and nonerosive and nondeforming arthritis. Almost all body systems can be affected includ-
ing renal, neurological, cardiac, respiratory, ophthalmic, gastrointestinal and hematological.
The estimated prevalence of SLE in the USA is 51/100,000, with females being affected 9 times 
more commonly than males. It is more common in people from Afro-Caribbean and Latin 
American decent. Most diagnosis is between the ages of 16–55 years with about 30% diagnosed 
younger than 16 or older than 55 years [107].
Diagnosis is based on clinical assessment and laboratory measures. Antibody tests including 
ANA, Anti-ds DNA and Anti-Sm may aid diagnosis but need to be used in the context of the 
clinical presentation [107].
Treatment for SLE depends on clinical presentation and disease activity, but the backbone 
is immunosuppression. However, given that the major cause of mortality in SLE is infection 
and malignancy which have both been attributed to long-term immunosuppression, there 
is a need to further understand disease etiology and find ways to prevent disease initiation 
and progression.
8.2. Pathogenesis of systemic lupus erythematosus
SLE occurs in genetically susceptible individuals, in whom an inflammatory response is 
triggered by a secondary stimulus. There is a strong genetic predisposition, and siblings of 
patients with SLE are 30 times more likely to have SLE than the general population [107]. 
Certain genetic variants which alter the inflammatory process and lead to impaired clearance 
of immunoglobulins have been implicated. Estrogen-driven stimulation of humeral activity 
may at least in part explain the female predominance [108]. Known environmental factors 
include UV light, demethylating drugs and infections such as EBV virus. These lead to the 
initiation of apoptosis and impaired clearance of cells. The nucleic acids are transferred to 
endosomal sensors, leading to the activation of endosomal toll-like receptors (TLRs) and den-
dritic cells which produce IFN alpha. These inflammatory mediators activate the inflamma-
tory cascade, immune complex production and vascular damage. Immune complexes cause 
tissue destruction by deposition in tissues [109].
8.3. Periodontitis and systemic lupus erythematosus
Several case reports have suggested that patients with SLE have a greater severity of peri-
odontitis [110–114]. The similar mechanisms of tissue destruction for periodontitis and SLE 
could explain a potential association. Polymorphisms in the Fcγ receptor leading to impaired 
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clearing of immune complexes have already been implicated in susceptibility to both peri-
odontitis and SLE [115]. The inflammatory cytokine profile is similar in periodontitis and SLE. 
For example, IL-18 levels are increased in patients with SLE and correlate with SLE disease 
activity index (SLEDAI) [116], while there is a significant correlation between IL-18 levels and 
periodontal parameters [116]. Interestingly, higher levels of IF-γ, IL 10, IL-17, IL-1β and IL-14 
found in healthy patients with periodontitis are also present in patients with SLE even in the 
absence of periodontitis [117]
TLRs which modulate the inflammatory response to microorganisms in periodontal disease 
have also been implicated in SLE. Activation of TLRs which respond to specific pathogen-
associated molecular patterns (PAMPs) such as Lipopolysaccharide produced by bacteria, 
triggers cell signaling pathways and release of pro-inflammatory cytokines. The overexpres-
sion of TLR-4 leads to autoimmune lupus and is essential for the production of anti-DsDNA 
antibodies found in SLE [108]. Therefore, the influence of the microorganisms in periodontal 
disease may affect the expression of TLRs in SLE and stimulate the autoimmune process.
Periodontitis is common in patients with SLE, with frequency varying between 60 and 93.8% 
[113, 118]. One Japanese study found that the frequency of periodontitis in SLE patients was 
70% as compared to 30% in the general population [115].
Cross-sectional studies have found that periodontitis is more common in SLE than in con-
trols [119–125]. A comparison of periodontal status in 105 SLE patients and geographically 
matched samples of the Adult Dental Health Survey in the UK found that, with adjustments 
for age and sex, patients with SLE were significantly more likely to have periodontitis with 
an OR 7.25 (95% CI 3.84–13.68) [121]. In another study, SLE patients had a significant 1.69-
fold increased odds (CI 1.37–3.25) of having periodontitis defined by CAL > 3 mm [125]. 
These findings have been replicated in juvenile SLE patients where periodontal parameters 
were significantly higher than in controls [122]. Interestingly, SLE disease activity as mea-
sured by SLEDAI index correlates with periodontal condition and is a significant predictor 
of periodontitis [125, 126].
Three further studies have found nonsignificant findings that periodontitis is more preva-
lent in SLE patients [119, 123, 121]. The lack of statistical significance may be due to small 
sample size, use of immunosuppressants which can affect periodontal disease activity, 
and age. In fact, one study did highlight the fact that although there was no statistical dif-
ference in periodontal status, SLE cases were significantly younger than controls and so 
one could conclude that periodontitis is premature in SLE patients [120]. A study which 
did not find that periodontitis is more prevalent in SLE patients may have been due to 
the use of anti-inflammatory agents and the fact that controls were skewed to being older 
than cases [127].
No differences in bacterial species have been found in SLE patients compared to controls 
when specific periodontitis-associated bacteria have been examined [116] However, there 
have been no studies to date which have sequenced the oral microbiome in SLE patients.
Nonsurgical treatment of periodontitis in patients with SLE significantly improves both peri-
odontitis measures and SLE disease activity index (SLEDAI) at 3 months [128]. This suggests 
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treatment of periodontitis leads to a reduction in SLE disease activity and periodontitis may 
be an important factor in maintaining the inflammatory process in SLE.
8.4. Conclusion
There are some very compelling biological arguments including the shared pathogenesis and 
specifically a possible role of TLRs which could explain the link between periodontitis and 
SLE. To date, the evidence from case control studies suggesting an association is promising. 
However, further work with larger studies and identification of the oral microbiome in SLE 
patients is required to explain the role of periodontitis both in the initiation and in the main-
tenance of the inflammatory process in SLE.
9. Periodontitis and osteoarthritis
Osteoarthritis (OA) is a chronic degenerative condition of the joints characterized by cartilage 
loss, bone remodeling and periarticular muscle weakness. In contrast to RA, PsA, AS and 
SLE, there is not thought to be a primary inflammatory element in the disease process in OA 
though, as a patient group, they are considered to be good controls for the inflammatory 
arthropathies due to a similar demography [129, 54].
Osteoarthritis is extremely common, affecting more than 10% of people over the age of 45 [130]. 
Diagnosis is made on clinical symptoms and signs, and typical X-ray findings can be helpful 
although not required.
OA usually occurs due to chronic stress on the joint but can be accelerated by trauma, infec-
tion, crystal deposition and inflammatory arthritidies. Interestingly physical factors alone are 
not responsible for the development of OA. In fact, family history is a significant predictor of 
disease development and genome-wide association studies have identified multiple significant 
loci associated with OA [131].
There are elements of oral microbial flora that are of interest. A recent study has demon-
strated the presence of periodontal bacteria in the joints of patients following joint replace-
ment that may play a role in loosening and replacement failure [132]. However, compared 
to RA, the risk of periodontitis is significantly lower in OA [62] and no association has been 
found between OA and mild, moderate or severe periodontitis [133].
10. Conclusion
The advent of 16S sequencing techniques has allowed further study of the interaction 
between the oral microbiome and inflammatory arthritidies. It is clear that periodontitis is 
associated with systemic inflammation. The underlying mechanisms for this are less clear 
but may be due to the interaction of microbes with the immune system in the periodontal 
pocket or as a result of bacteremia. There is strong evidence to suggest an association between 
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 periodontitis and rheumatoid arthritis with PAD producing P. gingivalis, having a key role 
in this interaction. There is also accumulating evidence for other inflammatory arthritidies 
including ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus. 
Common pathogenic mechanisms may explain this, but details of these interaction still need 
to be elucidated. Studies have been hampered by different measures of periodontitis, small 
sample size, multiple confounders and their cross-sectional nature. Further longitudinal 
studies which address these issues are needed. In the future, there may be a role for antibiot-
ics, probiotics or interventions, targeting specific bacteria in these autoimmune conditions.
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